Which Prescription Weight-Loss Medication Works Best?

Which prescription weight-loss medication tends to work best?

In one direct comparison, tirzepatide led to greater average weight loss than semaglutide among adults with obesity who did not have type 2 diabetes. The New England Journal of Medicine reported that, at week 72, average weight change was −20.2% with tirzepatide and −13.7% with semaglutide.

That is a trial result, not a guarantee or a ranking for every patient. The study enrolled 751 adults, was open-label, and compared maximum tolerated doses. Its results do not settle how a person with different health needs, treatment tolerance, or access will fare.

“Best” therefore has more than one measure. Average weight change is one; tolerability and whether treatment is accessible are others. A clinician can weigh those factors against a person’s medical history and treatment goals.

How do semaglutide and tirzepatide compare for weight loss?

In the New England Journal of Medicine’s 2025 report of the 72-week SURMOUNT-5 trial, tirzepatide showed a larger average reduction in weight and waist circumference than semaglutide. Average waist circumference fell by 18.4 cm with tirzepatide and 13.0 cm with semaglutide. These group averages describe the trial, not an individual prediction.

Gastrointestinal effects were the most common with both medicines in the trial, usually mild to moderate and occurring mainly during dose escalation. The direct comparison helps with one question—average results under trial conditions. It does not show that everyone will tolerate either medicine equally well, or that the larger average is the right trade-off for every person.

Semaglutide’s prescribing information lists nausea, diarrhea, vomiting, constipation, and abdominal pain among common adverse reactions. In adult weight-reduction trials, nausea was reported by 44% of injection recipients versus 16% receiving placebo, according to the DailyMed WEGOVY prescribing information. The label also warns of potentially serious problems, including pancreatitis, gallbladder disease, and severe gastrointestinal reactions. Concerning symptoms warrant contact with a clinician.

Dose escalation is part of tolerability, not a race to a target. The WEGOVY label says increases are staged at four-week intervals to reduce gastrointestinal adverse reactions and that escalation can be delayed when a dose is not tolerated. A prescriber’s individualized directions take precedence over a general comparison.

How long does it take for weight-loss medication to work?

Trial evidence measures change across months, not days: the head-to-head comparison reported its main average outcomes at week 72. That timeframe gives a better sense of how researchers assessed sustained results than a quick early change would.

The WEGOVY label describes a gradual start and staged increases at four-week intervals, with delay possible if a patient cannot tolerate a dose. This means treatment involves a period of adjustment; early side effects and early scale changes do not by themselves establish the eventual result.

There is no single timeline in the supplied evidence that predicts when a particular person will notice meaningful change. Results depend on the person and the treatment course. A clinician can track progress and tolerance over time rather than treating a trial average as a deadline.

Access also shapes how long treatment can continue. In its 2025 Employer Health Benefits Survey, KFF found that coverage for GLP-1 drugs when used primarily for weight loss varied by employer size: 16% of firms with 200–999 workers, 30% of firms with 1,000–4,999 workers, and 43% of firms with at least 5,000 workers covered them. Among firms that did cover these medicines, 34% required a meeting with a dietitian, case manager, or therapist, or participation in a lifestyle program.

Price can make continued treatment difficult. KFF reported U.S. list prices of roughly $936–$1,349 per month in 2024 before insurance coverage, rebates, or coupons. Actual out-of-pocket costs vary. In KFF’s 2024 poll, 54% of adults who had used GLP-1 medicines said they found them difficult to afford. Coverage and plan rules matter as much as a list price when estimating a person’s cost.